An open-label phase II trial of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity
Sotrovimab pre-exposure prophylaxis had a favorable safety profile and was well tolerated at both doses, with low immunogenicity. These findings support mAbs' safety as COVID-19 pre-exposure prophylaxis in this population.
Authors
- Ahmed Nader
- Rayven Frierson (ORCID: https://orcid.org/0000-0002-8849-1857)
- Katherine Beluch
- Chloé Lahoud (ORCID: https://orcid.org/0000-0003-2346-8733)
- Isabel H Gonzalez-Bocco (ORCID: https://orcid.org/0000-0002-2073-092X)
- Alyssa Cho
- Sarah P. Hammond (ORCID: https://orcid.org/0000-0002-4271-7443)
- Sophia Koo (ORCID: https://orcid.org/0000-0002-4973-7439)
- Alicia Aylott
- Michael Dougan (ORCID: https://orcid.org/0000-0001-9266-2009)
- Jennifer Manne‐Goehler (ORCID: https://orcid.org/0000-0001-9295-0035)
- Keri M. Sullivan (ORCID: https://orcid.org/0000-0003-1316-0196)
- Jennifer Han (ORCID: https://orcid.org/0000-0003-4744-8067)
- Brian T. Chan (ORCID: https://orcid.org/0000-0002-6971-3039)
- C. Elizabeth Keleher
- Dimitrios G Moshovitis
- Fabiola A. Reyes
- Manu Balusu
- Qianwen Wang (ORCID: https://orcid.org/0000-0003-3553-1162)
- Andres E Franceschi
- Wei Wang (ORCID: https://orcid.org/0000-0002-3827-0474)
Institutions
- Brigham and Women's Hospital (US)
- Tufts Medical Center (US)
- Harvard University (US)
- GlaxoSmithKline (United Kingdom) (GB)
- Hospital of the University of Pennsylvania (US)
- Age UK (GB)
- Staten Island University Hospital (US)
- University of Saint Mary (US)
- Massachusetts General Hospital (US)
- St. Mary's Hospital (US)
- GlaxoSmithKline (United States) (US)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- New Microbes and New Infections
- Published
- 2025-08-08
- DOI
- https://doi.org/10.1016/j.nmni.2025.101620
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00